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ABSTRACT
Recombinant adeno-associated viral (rAAV) vectors have garnered much promise in gene therapy applications. However, wide-
spread clinical use has been limited by transduction efficiency. Previous studies suggested that the majority of rAAV accumu-
lates in the perinuclear region of cells, presumably unable to traffic into the nucleus. rAAV nuclear translocation remains ill-
defined; therefore, we performed microscopy, genetic, and biochemical analyses in vitro in order to understand this mechanism.
Lectin blockade of the nuclear pore complex (NPC) resulted in inhibition of nuclear rAAV2. Visualization of fluorescently la-
beled particles revealed that rAAV2 localized to importin--dense regions of cells in late trafficking steps. Additionally, small
interfering RNA (siRNA) knockdown of importin- partially inhibited rAAV2 nuclear translocation and inhibited transduction
by 50 to 70%. Furthermore, coimmunopreciptation (co-IP) analysis revealed that capsid proteins from rAAV2 could interact
with importin- and that this interaction was sensitive to the small GTPase Ran. More importantly, mutations to key basic re-
gions in the rAAV2 capsid severely inhibited interactions with importin-. We tested several other serotypes and found that the
extent of importin- interaction varied, suggesting that different serotypes may utilize alternative import proteins for nuclear
translocation. Co-IP and siRNA analyses were used to investigate the role of other karyopherins, and the results suggested that
rAAV2 may utilize multiple import proteins for nuclear entry. Taken together, our results suggest that rAAV2 interacts with im-
portin- alone or in complex with other karyopherins and enters the nucleus via the NPC. These results may lend insight into
the design of novel AAV vectors that have an enhanced nuclear entry capability and transduction potential.
IMPORTANCE
Use of recombinant adeno-associated viral (rAAV) vectors for gene therapy applications is limited by relatively low transduction
efficiency, in part due to cellular barriers that hinder successful subcellular trafficking to the nucleus, where uncoating and sub-
sequent gene expression occur. Nuclear translocation of rAAV has been regarded as a limiting step for successful transduction
but it remains ill-defined. We explored potential nuclear entry mechanisms for rAAV2 and found that rAAV2 can utilize the clas-
sical nuclear import pathway, involving the nuclear pore complex, the small GTPase Ran, and cellular karyopherins. These re-
sults could lend insight into the rational design of novel rAAV vectors that can more efficiently translocate to the nucleus, which
may lead to more efficient transduction.
Adeno-associated virus (AAV) is a Dependovirus in the familyParvoviridae that cannot replicate on its own (1). For this
reason, recombinant adeno-associated viruses (rAAV) have re-
cently garnered much attention in the field of gene therapy (re-
viewed in reference 2). Several serotypes have been discovered that
transduce various tissue types with high efficiency (reviewed in
reference 3). Despite its promise, widespread use of AAV vectors
has been hindered by their relatively low transduction efficiency.
Thus, much interest in the field has been directed toward the ra-
tional and combinatorial design of enhanced AAV vectors that can
overcome transduction barriers at the level of receptor binding,
subcellular trafficking, and transgene expression.
It has become apparent that subcellular trafficking presents
multiple barriers to successful rAAV transduction, which involves
movement of the vector from the host cell surface into the nu-
cleus, where uncoating and subsequent gene expression occur (4–
7). These events are mediated by interactions between host cell
proteins and the three capsid proteins, VP1, VP2, and VP3 (8, 9).
In the case of rAAV2, the vector binds to primary and coreceptors,
such as heparan sulfate proteoglycan and v5-integrins (10–12).
The particle is internalized through receptor-mediated endo-
cytosis via clathrin-coated pits or through the clathrin-inde-
pendent carriers/glycophosphatidylinositol-enriched early
endosomal compartments (CLIC/GEEC) pathway (13, 14).
rAAV2 then traffics along the endo-lysosomal route, accumu-
lating near the Golgi compartment and the microtubule orga-
nizing center (MTOC) (15–20). rAAV2 harbors domains bur-
ied within the capsid surface that are critical for further
subcellular trafficking and nuclear entry (21–23). At some
point prior to escape from the endosome, rAAV2 undergoes a
conformational change, leading to the exposure of the unique
N-terminal ends of VP1 and VP2; this conformation is termed
VP1up (22, 23). VP1up contains a phospholipase A2 (PLA2)
domain that is thought to mediate escape from the endosomal
compartment (24), as well as 3 putative nuclear localization
sequences (NLSs) (25, 26). Upon endosomal escape, rAAV2
enters the nucleus as an intact particle (27), where subsequent
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uncoating and gene expression occur. Currently, the mecha-
nism of nuclear entry by rAAV vectors is unknown. Studies
into the intracellular trafficking of rAAV2 have revealed a com-
mon pattern: while the majority of particles traffic to a perinu-
clear region associated with the MTOC, most of these particles
remain distal to the nucleus and never translocate (4, 5, 28).
These particles are eventually degraded by host proteasomes
and are likely presented as antigens on the cell surface (29). If
this barrier to nuclear entry could be overcome, two benefits
could be achieved. First, extra vectors in the nucleus could
potentially bolster transduction efficiency by contributing to
greater transgene expression. Second, movement of particles
from the cytosol into the nucleus could reduce the number of
capsids susceptible to antigen presentation and host cell immu-
nity. Therefore, an understanding of the mechanism of nuclear
entry by AAV would create a foundation to design improved
capsids that can overcome this barrier.
The majority of nuclear-targeted cellular proteins utilize the
canonical nuclear import pathway (for a review, see references 30
and 31). Proteins with a NLS are bound by karyopherins, most
typically a member of the importin- family or an importin-
adapter/importin- heterodimer. The importin proteins serve as
chaperones to bring the nuclear-bound “cargo” through the nu-
clear pore complex (NPC), a multiprotein complex that can ac-
commodate import of proteins up to 39 nm (32). This process is
dependent on the small GTPase Ran, which provides the energy
required for the translocation and mediates the dissociation of the
importin- complex once it is inside the nucleus (33–36).
Many viruses take advantage of all or parts of this pathway (for
reviews, see references 37 and 38). For example, the DNA-bound
protein VII of adenovirus enters the nucleus through the NPC via
interactions with importin-, importin-, and importin-7 (39).
Herpes simplex virus 1 (HSV-1) mediates nuclear entry of its nu-
cleic acid through directly binding to the cytoplasmic filaments of
the NPC in an importin--dependent manner (40, 41). The hep-
adnavirus hepatitis B virus (HBV) has been shown to bind to the
NPC in a manner mediated by the phosphorylation of its capsid
and the exposure of two NLSs that bind to importin- and impor-
tin- (42–44). Interestingly, the autonomous parvovirus minute
virus of mice (MVM) has been shown to utilize an alternative
nuclear entry mechanism involving direct disruption of the nu-
clear lamina in a caspase-dependent manner (45, 46).
Several studies have yielded insights into how AAV translo-
cates into the nucleus; however, the mechanism of nuclear entry
remains ill-defined and could differ between wild-type (wt) viri-
ons and AAV vectors. With a capsid diameter of 26 nm, AAV
particles are within the size limit to traverse the NPC. The unique
N termini of AAV2 VP1 and VP2 contain three basic regions (BRs)
that resemble classic NLSs and can support nuclear entry of exog-
enous proteins (23, 47). Mutations to these basic regions inhibit
nuclear entry of rAAV2 and subsequent transduction (25, 26).
These results suggest that the mechanism of nuclear entry by
rAAV2 involves components of the canonical nuclear import
pathway, such as importin proteins and the NPC. In contrast, a
study using wt AAV2 showed that inhibition of the nuclear pore
by wheat germ agglutinin (WGA) or an antibody against nucleo-
porin p62 in purified nuclei did not prevent nuclear accumulation
of intact virions (7). In a study utilizing wt AAV2 in the presence of
adenovirus, inhibition of nuclear entry via the NPC through use of
the calcium channel inhibitor thapsigargin did not prevent the
appearance of viral genomes in the nucleus but did affect the level
of nuclear accumulation and replication (48). Recently, a PDZ-
binding domain was discovered on the N terminal of VP1 that was
shown to be important for nuclear entry of wt AAV2 (49). While
the current study was under review, a recent study revealed that
AAV2 that had been acidified and then neutralized could cause
nuclear envelope breakdown in permeabilized HeLa cells (50). As
in vitro assays become more harmonized with respect to physio-
logical infection, these results, taken together, suggest that AAV
may utilize multiple import mechanisms to gain access to the nu-
cleus, or that the mechanism of nuclear entry might vary for wt
AAV2 and AAV vectors.
Therefore, we sought to further understand the mechanism of
nuclear entry for rAAV in the absence of a helper virus in the
context of gene therapy applications. Here we show that rAAV2
utilizes the host cell canonical nuclear entry pathway to enter host
cell nuclei. Unlike the autonomous parvovirus MVM, rAAV does
not appear to disrupt host cell nuclear lamina and is not depen-
dent on caspase activity for nuclear entry. Rather, inhibition of the
nuclear pore through microinjection of WGA partially inhibited
the nuclear translocation of viral particles. Moreover, nuclear im-
port of rAAV2 was dependent on importin-; its import may also
be facilitated by several importin- proteins as well as importin-7.
Interactions between rAAV2 capsid proteins and importin- were
mediated by VP1 and VP2, specifically, the BR domains therein.
Interestingly, the extent of interaction with importin- varied
among the rAAV serotypes tested. Taken together, our results sug-
gest that entry through the canonical pathway plays a role in
rAAV2 nuclear translocation.
MATERIALS AND METHODS
Cell culture. HeLa and HEK-293 cells were maintained at 37°C and 5%
CO2 in Dulbecco’s modified Eagle’s medium (DMEM) that was supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 g/ml streptomycin. For imaging experiments, HeLa
cells were maintained in phenol red-free DMEM for at least 2 passages
prior to plating.
Drug treatment. HeLa cells (3  104 cells/well) were treated with
either z-vad-fmk (200 M; Tocris Bioscience) or dimethyl sulfoxide
(DMSO) 2 h prior to infection with rAAV2. To confirm the functionality
of z-vad-fmk, HeLa cells were treated with etoposide (200 M; Tocris)
following a 2-h pretreatment with z-vad-fmk or DMSO. Prevention of
apoptosis was visually inspected 48 h after etoposide treatment and quan-
titatively confirmed through use of 7-amino-actinomycin D (Life Tech-
nologies) via flow cytometry.
PCR site-directed mutagenesis. Capsid mutations were generated in
the pACG2 backbone as previously described (27), with minor modifica-
tions. PCR was performed with the QuikChange Lightning site-directed
mutagenesis kit (Stratagene). PCR products were digested with DpnI and
transformed into DH10B bacteria, which were selected on ampicillin-
containing agar plates. Single colonies were picked and grown in liquid
cultures overnight, and plasmids were isolated by column purification
(Qiagen). Mutations were verified by sequencing of the plasmids with the
Eton Bioscience automated DNA sequencing facility.
Virus production. Virus was produced in HEK-293 cells as previously
described (51). Briefly, polyethylenimine max was used for the triple
transfection of the pXR2 cap and rep plasmids, the pXX6-80 helper plas-
mid, and a TR-luciferase reporter plasmid containing the firefly luciferase
(Luc) transgene flanked by inverted terminal repeats. Cells were harvested
between 48 and 72 h posttransfection, and virus was purified by iodixanol
gradient centrifugation followed by ion-exchange chromatography. After
identifying peak fractions by dot blot hybridization, virus was dialyzed
into phosphate-buffered saline (PBS) containing 5% sorbitol, MgCl2 (1
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mM), and CaCl2 (0.5 mM). Titers were calculated by quantitative PCR
(qPCR) according to established procedures (52) using a LightCycler 480
instrument with Sybr green (Roche) and primers designed against the Luc
transgene: 5=-AAA AGC ACT CTG ATT GAC AAA TAC-3= (forward) and
5=-CCT TCG CTT CAA AAA ATG GAA C-3= (reverse). Conditions used
for the reaction were as follows: 1 cycle at 95°C for 10 min; 45 cycles at
95°C for 10 s, 62°C for 10 s, and 72°C for 10 s for acquisition; 1 cycle at
95°C for 30 s, 65°C for 1 min, and 99°C for melting curve analysis. For
Cy5-labeled virus, purified rAAV2, VP3-only particles, and BR mutants
were labeled with Cy5 dye (GE Amersham) as previously described (28).
Confocal immunofluorescence microscopy. Similar to what we pre-
viously described (26), HeLa cells (3  104 cells/well) were plated onto
poly-L-lysine-coated 12-mm glass coverslips (no. 1.5) for 16 h before in-
fection. At 30 min before infection, HEPES was added to the medium (10
mM, total concentration). Cy5-labeled recombinant virions were added
to cell medium (100,000 vector genome copies [vg]/cell) for 1 h. No virus
was added to control wells. Medium was then replaced with prewarmed
medium, and cells were placed at 37°C. At the indicated time points, cells
were washed three times with PBS and then fixed with 2% paraformalde-
hyde for 15 min at room temperature. The cells were permeabilized with
0.1% Triton X-100 in PBS for 5 min at room temperature. Following four
washes with PBS, the permeabilized cells were blocked with immunofluo-
rescence buffer (IFB; 20 mM Tris [pH 7.5], 137 mM NaCl, 3 mM KCl, 1.5
mM MgCl2, 5 mg/ml bovine serum albumin, 0.05% Tween) for 30 min at
room temperature. Where indicated, the cells were incubated with impor-
tin- primary antibody diluted in IFB overnight at 4°C. The cells were
then incubated in secondary antibody diluted 1:5,000 in IFB (anti-mouse
Dylight 488 or anti-rabbit Dylight 488; Abcam) for 1 h at 37°C. After six
washes in PBS, coverslips were mounted cell side down onto glass slides
with mounting medium (Prolong Antifade gold with DAPI [4=,6=-di-
amidino-2-phenylindole]; Molecular Probes). Images were captured on a
Zeiss 710 upright laser scanning confocal microscope. Three-dimensional
(3D) rendering and image processing of confocal z-stack images were
performed using AutoQuant and Imaris software, respectively (UNC Mi-
croscopy Services Laboratory).
Microinjections with pulse infection. HeLa cells (7.5  104) were
plated on fibronectin-coated 35-mm glass-bottom microwell dishes with
a number 1.5 coverglass (MatTek). Cells were microinjected using the
FemptoJet system with Femptotips (Eppendorf). For virus studies, 30 min
before infection cells were cooled to 4°C. Cy5-labeled AAV2 (100,000
vg/cell) was added to each dish for 1 h. Where indicated, microinjection
mixes (10 l) included fluorescein isothiocyanate (FITC)-dextran (0.8
mg/ml; Life Technologies), wheat germ agglutinin (2 mg/ml; Calbi-
ochem), and phosphate-buffered saline. For rhodamine B-labeled, NLS-
conjugated bovine serum albumin (BSA) comicroinjections, mixtures
included rhodamine B-BSA (1.33 mg/ml; Sigma). Following microinjec-
tion, medium was replaced with fresh, prewarmed medium. At 2 h post-
microinjection, cells were fixed and processed for microscopy as described
above.
Transduction assays. For small interfering RNA (siRNA) studies,
HeLa cells were plated in 24-well plates 18 h prior to transfection at den-
sities that approximated 30% confluence (3  104 cells/well) in antibiotic-
free DMEM. siRNA (total concentration, 25 nM; ON-TargetPlus Smart-
Pool; Dharmacon) to KPNB1 (importin-), KPNA2 (importin-1),
KPNA4 (importin-3), KPNA1 (importin-5), and IPO7 (importin-7)
was utilized in combination with 1 l DharmaFECT 1 (Dharmacon) as
per the manufacturer’s instructions. At 24 h posttransfection (for impor-
tin-) or 48 h posttransfection (for importin-1, -3, -5, and importin-
7), cells were infected with purified rAAV2 at the designated number of
vector genomes per cell and typically harvested after 24 h unless otherwise
noted. For drug studies, 5  104 HeLa cells were plated in 24-well plates 18
h prior to drug treatment. For treatment with z-vad-fmk (Tocris Biosci-
ence; 200 nM in DMSO), cells were treated 2 h prior to infection; for
treatment with chloroquine (Sigma; 100 M in PBS), cells were treated at
the same time as infection. Luciferase activity was measured in accordance
with the manufacturer’s instructions (Promega) with a PerkinElmer 1420
Victor3 automated plate reader. Error bars in the figures represent stan-
dard deviations of samples scored in triplicate. Graphs are representative
of data sets from at least three independent assays.
Coimmunoprecipitation. Protein G-Dynabead-antibody complexes
were prepared by washing the beads 2 times in PBS and resuspending
them in PBS with 0.02% Tween 20 and antibody (30 l of beads and 3 g
of antibody per reaction mixture). The Dynabeads were rocked at 4°C
overnight. For studies of rAAV2 and mutants, HeLa cells (1  107 per
coimmunoprecipitation [co-IP] mixture) were washed 2 times with ice-
cold PBS and harvested in lysis buffer (Tris [pH 7.4], 50 mM; MgCl2, 10
mM; NaCl, 150 mM; Triton X-100, 0.1%; deoxycholate, 0.1%; protease
inhibitor cocktail [Pierce], 1). Lysate was incubated for 30 min at 4°C
and clarified by centrifugation. Lysate was precleared by incubating with
beads for 30 min at 4°C. rAAV2 or mutants (2.5  1011) were boiled in
lysis buffer for 10 min. Lysate was then added to virus and incubated for 2
h at 4°C. A 10% aliquot of each co-IP reaction mixture was collected to
serve as the input amount. Dynabeads were washed 2 times with lysis
buffer and then added to the virus-lysate mix for 2 h at 4°C. Dynabeads
were then washed 3 times with lysis buffer and transferred to a new tube.
Eluates were collected by resuspending the Dynabeads in 50 l 2 Nu-
Page lithium dodecyl sulfate sample buffer (Life Technologies), and sam-
ples were boiled for 10 min. Samples were then subjected to SDS-PAGE
and immunoblot analysis using the B1 antibody (a kind gift from Jürgen
A. Kleinschmidt). For RanQ69L studies, HEK-293 cells were used. Cells
were plated 24 h prior to transfection (2.5  104 cells per 10-cm plate, 2
plates per co-IP). Polyethylenimine Max was used to transfect pmCherry-
C1-RanQ69L (a kind gift from Jay Brenman) or pmCherry-C1. At 40 h
posttransfection, cells were harvested in lysis buffer and processed as de-
scribed above. One milligram of total lysate was used for each co-IP reac-
tion.
Statistics. All statistical analyses were performed using the Student t
test. Statistical significance was defined as a P value of 0.05.
RESULTS
Previous studies have shown that the majority of rAAV2 virions
traffic to the perinuclear region of cells but never enter the nu-
cleus. These virions likely become degraded by proteases or are
subjected to proteasomal degredation and antigen presentation by
host cells (29). Current opinion suggests that if the barrier to nu-
clear entry were to be overcome, more viruses could translocate to
the nucleus for subsequent uncoating and transgene expression.
To date, the mechanism of nuclear entry by rAAV is largely un-
known. However, a few reports have suggested potential mecha-
nisms by which rAAV enters the nucleus, including entry via the
NPC through the classic nuclear entry pathway (25, 26), entry
through NPC-independent mechanisms (7, 48), and direct lam-
ina disruption, like that of the autonomous parvoviruses (46).
Focusing our studies on AAV in the context of gene therapy vec-
tors, we aimed to determine the mechanism for nuclear entry by
rAAV2 in the absence of a helper virus.
Analysis of host cell nuclear lamina during rAAV2 infection.
Previous studies have described a unique nuclear entry mecha-
nism for the autonomous parvovirus MVM, whereby MVM en-
ters the nucleus through physical disruption of the nuclear lamina
in a caspase-dependent mechanism (46). Since AAV is a parvovi-
rus, we sought to determine whether rAAV2 utilized a similar
mechanism. To investigate the integrity of the nuclear lamina
upon rAAV2 infection, we utilized confocal microscopy to visual-
ize Lamin A/C and Lamin B1 during infection with Cy5-labeled
rAAV2 (Fig. 1A). Immunofluorescence analysis revealed no de-
tectable changes in the appearance of Lamin A/C or Lamin B1
2 h postinfection, a time that has been reported to capture 50%
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of total viral nuclear entry (28). We next utilized quantitative
imaging analysis to measure the percentage of nuclear Cy5 flu-
orescence within HeLa cells treated with the caspase inhibitor
z-vad-fmk. Our lab has established that confocal analysis of
Cy5-labeled rAAV2 particles can be used to quantify the per-
centage of nuclear rAAV2 (28), and our quantification of the
percentage of Cy5 fluorescence within nuclei of vehicle-treated
cells was consistent with what has been previously reported
(53, 54). Treatment with z-vad-fmk, which was shown to in-
hibit lamina disruption and nuclear entry of MVM, resulted in
no change in nuclear Cy5 fluorescence compared with vehicle-
treated cells (Fig. 1B and C). In fact, pretreatment of HeLa cells
with z-vad-fmk followed by infection with rAAV2-Luc led to a
small but nonsignificant increase in transduction compared to
the vehicle control (Fig. 1D). We confirmed the functionality
of the z-vad-fmk used in these studies through 7-amino-acti-
nomycin D analysis of apoptosis prevention in etoposide-
treated cells (data not shown). Taken together, these results
suggest that, unlike the autonomous parvovirus MVM, rAAV2
does not overtly disrupt host cell nuclear lamina nor rely on
caspase activation for nuclear entry or transduction.
rAAV2 can utilize the nuclear pore complex to enter the nu-
cleus. Many viruses utilize the nuclear pore complex to traffic
intact particles, viral proteins, or DNA into the nucleus (37, 38).
The nuclear pore has been shown to accommodate proteins of
sizes up to 39 nm in diameter (32). Because the diameter of the
AAV capsid is approximately 26 nm and it has been shown that
rAAV2 can enter the nucleus as an intact particle (27), we inves-
tigated whether rAAV2 could enter the nucleus by using the NPC.
A common method to determine if the NPC is necessary to facil-
itate nuclear entry is to physically block the outer pore with the
lectin WGA (55). WGA binds to O-linked N-acetylglucosamine
residues on NPC proteins, thereby blocking any incoming cargo.
We confirmed this by microinjecting HeLa cells with rhod-
amineB-labeled, NLS-conjugated BSA with either FITC-labeled
dextran or dextran and WGA (Fig. 2A). In cells that were injected
with dextran alone, the NLS-BSA could be visualized inside the
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FIG 1 Nuclear lamina integrity and caspase involvement during rAAV2 infection. (A) Immunofluorescence of Cy5-labeled rAAV2 and intact nuclear lamina 2
h postinfection. Capsids (red) are shown juxtaposed to the nuclear membrane, composed of Lamin A/C (top, green) and Lamin B1 (bottom, green). Bar, 10 m.
(B) Nuclear entry of Cy5-labeled rAAV2 in cells treated with vehicle or z-vad-fmk. HeLa cells were treated with z-vad-fmk or vehicle (DMSO) 1 h prior to and
throughout infection. Cells were fixed at 2 h and 21 h postinfection. Red, Cy5-labeled rAAV2; green, Lamin A/C. Bar, 10 m. (C) Quantification of nuclear Cy5
fluorescence in z-vad-fmk- or vehicle-treated cells. Confocal z-stack images for 20 cells per treatment group were acquired. Images were rendered in 3D, and
isosurfaces were created for nuclei and Cy5 fluorescence within each cell. The percent Cy5 fluorescence within nuclei compared to total Cy5 fluorescence within
the cell was calculated. (D) Luciferase assay of transduction in HeLa cells. Cells were treated with either z-vad fmk or vehicle 1 h prior to infection and then
infected with rAAV2-CBA-Luc (1,000 vg/cell). Luciferase activity was measured 24 h postinfection. Error bars represent standard deviations from a represen-
tative experiment performed in triplicate.
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jected with dextran and WGA, the NLS-BSA was mostly excluded
from the nucleus. We then applied this technique to HeLa cells
subjected to viral infection with Cy5-labeled rAAV2. We pre-
bound HeLa cells with Cy5-labeled rAAV2 and performed micro-
injections with either dextran alone or dextran and WGA. At 2 h
postmicroinjection, we processed the cells for confocal micros-
copy to assess nuclear localization through visualization of the
Cy5-labeled particles. In cells that were microinjected with dex-
tran, viral particles could be seen inside of the nucleus (Fig. 2B,
top). However, in cells that were microinjected with WGA, fewer
viral particles could be seen inside the nucleus, suggesting that
nuclear entry was limited (Fig. 2B, bottom). We quantified the
percentage of nuclear Cy5 fluorescence in microinjected cells and
found an average of 15% nuclear Cy5 fluorescence in dextran-
injected cells, while cells injected with dextran plus WGA showed
an average of 8% nuclear Cy5 fluorescence (Fig. 3C). Taken to-
gether, these results suggest that rAAV2 can utilize the NPC to
enter the nucleus.
rAAV2 shares spatial distribution with importin- during
later trafficking events. Importin- plays a key role in canonical
nuclear entry by either directly binding to NLS-harboring cargo or
interacting with cargo through an adapter importin- protein.
Importin- has been shown to be involved in nuclear import for
several viral infectious pathways, including facilitating the binding
of HSV-1 capsids (41), HBV core particles (42), HIV-1 preinte-
gration complexes (56), and influenza A virus nucleoprotein (57)
to host nuclei. Importantly, importin- has been shown to inter-
act with a DNA-bound protein of the AAV helper virus adenovi-
rus (39). Therefore, we aimed to determine if rAAV2 localized
near cellular regions with a high importin- concentration during
the course of infection. We utilized Cy5-labeled rAAV2 and im-
munofluorescence confocal microscopy to acquire z-stack images
of HeLa cells infected with rAAV2 at various time points. These
images were rendered in three dimensions by using volume imag-
ing software. During the course of infection, rAAV2 traffics from
the cell periphery to the MTOC and nearby cellular compartments
before translocating to the nucleus (15, 18, 20). As expected, at 30
min postinfection, when the majority of rAAV2 was detected dis-
persed throughout the cytoplasm, there appeared to be little to no
detectable codistribution between rAAV2 and importin- (Fig.
3A). However, as early as 1 h postinfection and through 9 h postin-
fection, Cy5-rAAV2 was localized in cellular regions with a high
importin- concentration. These results suggested that rAAV2
and importin- interact once AAV2 has accumulated near the
MTOC.
Previous reports have suggested that endosomal escape pre-
cedes nuclear entry of rAAV2 (16, 23). We therefore investigated
whether the codistribution of rAAV2 and importin- was depen-
dent on later trafficking events that could involve escape from the
endosome; we acquired 2D images of cells in the z-plane harbor-
ing the center of the nucleus to represent the center of the cell.
Endosomal escape has been shown to be inhibited by pharmaco-
logical agents that block vesicle acidification (16, 29). We there-
fore utilized chloroquine, a small molecule that blocks the acidi-
fication of endosomes, to inhibit later trafficking events and
endosomal escape of rAAV2. Treatment of cells with chloroquine
resulted in the loss of codistribution between rAAV2 and impor-
tin- (Fig. 3B). These results suggested that rAAV2 and impor-
tin- interact in later trafficking steps, presumably once rAAV2
has exposed the unique N terminal of VP1 and escaped the endo-
some.
rAAV2 interacts with importin- in a Ran-sensitive manner.
Because we observed a codistribution pattern between Cy5-
rAAV2 and importin- in later viral trafficking steps, we sought to
determine if rAAV2 and importin- form a physical interaction.
We hypothesized that because rAAV2 contains putative NLSs on
VP1 and VP2, an interaction could occur in late trafficking events,
perhaps once rAAV2 has undergone conformational changes to
expose these regions of the capsid. Previous studies have shown

































FIG 2 rAAV2 can enter HeLa cell nuclei through the NPC. (A) Rhodamine-
labeled, NLS-conjugated BSA (red) was comicroinjected with dextran (Dex)
alone (top, green) or dextran and WGA (bottom, green) into HeLa cells. Cells
were fixed and imaged 2 h after microinjection to assess NLS-BSA localization.
Bar, 10 m. (B) Cells were cooled to 4°C and infected with Cy5-labeled rAAV2
(red). One hour later, cells were microinjected with dextran (green, top) or
dextran plus WGA (green, bottom). Immunofluorescence microscopy was
used to assess Cy5-rAAV2 nuclear entry 2 h postinfection. Shown are maxi-
mum intensity projections of 3D-reconstructed cells, where red depicts Cy5
fluorescence within the cytoplasm and white depicts nuclear Cy5 fluorescence.
Bar, 10 m. (C) Quantification of microinjected cells. Confocal z-stack images
of microinjected cells were rendered in 3D, and isosurfaces were created for
nuclei and Cy5 fluorescence within the cell. The percent Cy5 fluorescence
within nuclei compared to total Cy5 fluorescence within the cell was calculated
(n  10 for dextran-injected cells; n  12 for WGA-injected cells).
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an NLS on the cargo and can be dissociated by the small GTPase
Ran in its GTP-bound form (35, 36). Therefore, we performed
co-IP experiments with dissociated capsid proteins (to expose
VP1 and VP2) and HEK-293 lysate transfected with a permanently
GTP-bound form of Ran (Q69L) or a control plasmid (Fig. 4).
rAAV2 capsid proteins were able to co-IP with importin-; how-
ever, this interaction was completely inhibited in the presence of
RanQ69L. This result suggested that rAAV2 capsid proteins form
a specific interaction with importin- that can be disrupted by
RanGTP.
Knockdown of importin- inhibits nuclear entry and trans-
duction of rAAV2. Because we observed similar spatial distribu-
tions between rAAV2 and importin-, we next investigated
whether importin- played a physiological role in rAAV2 traffick-
ing and transduction. We utilized an siRNA approach to tran-
siently silence importin- expression in HeLa cells. Previous
studies have shown that long-term inhibition of importin- ex-
pression can disrupt cellular homeostasis, since importin- plays
a vital role in the nuclear import of essential nuclear proteins.
Therefore, we chose to examine the effects of importin- knock-
down on rAAV2 transduction within the first 24 h post-siRNA
treatment, and we found approximately 50% knockdown of im-
portin- at the time of rAAV2 infection (Fig. 4A). While we can-
not rule out inhibition of rAAV-specific transcription factor im-
port by importin- knockdown, we verified that global gene
transcription was not altered by utilizing qRT-PCR to measure
mRNA levels of the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and determined that these levels
were similar between results with importin- knockdown and
treatment with a scrambled siRNA (data not shown). To assess
effects on transduction, we utilized rAAV2 carrying a CBA-lucif-
erase transgene. rAAV2 transduction was inhibited when lucifer-
ase activity was measured at either early (12 h) or late (24 h) time
points, with the greatest inhibition (approximately 70%) at 24 h
postinfection (Fig. 5B). We next assessed whether this inhibition
was maintained at various viral doses. Consistent with our initial
results, knockdown of importin- inhibited rAAV2 transduction
to levels between 50 and 70% at all vector doses higher than 500
vg/cell (Fig. 5C). Finally, we knocked down importin- and inves-
tigated changes in the nuclear localization of Cy5-labeled rAAV2.
Consistent with the changes in transduction, siRNA knockdown
of importin- inhibited Cy5- rAAV2 nuclear localization (Fig.
5D). To quantify these observations, we determined the percent-
ages of nuclear Cy5 fluorescence in cells treated with siRNA to
importin- or a scramble control. In control cells, nuclear Cy5
fluorescence increased from 21% at 2 h postinfection to 27% at 8
h postinfection. Nuclear Cy5 fluorescence in importin- knock-
down cells remained lower, increasing from 14% to 18% at 8 h
postinfection. Complete inhibition of nuclear entry and transduc-
tion was not observed, which reflects either the activity of the
remaining importin- in knockdown cells or the utilization of
alternative, importin--independent nuclear entry pathways by
rAAV2. These results do suggest that importin- plays a role in
rAAV2 transduction as a mediator of nuclear entry.
Determination of unique regions of the AAV2 capsid that are
important for the interaction with importin-. Since we were














FIG 3 rAAV2 codistributes with importin- in later trafficking steps. (A) HeLa cells were pulse-infected with Cy5-labeled rAAV2 for the indicated times.
Confocal z-stack images were acquired and rendered in three dimensions to assess the localization of rAAV2 (red) and importin- (green) in relation to the
nucleus (blue). Bar, 10 m. (B) HeLa cells were treated with chloroquine (100 uM) or vehicle (PBS) 2 h prior to and throughout the duration of infection. Cells
were pulse-infected with Cy5-rAAV2 for the indicated times. Confocal images were acquired in the z-plane that harbored the center of the nucleus of the to assess
the 2D localization of Cy5-rAAV2 (red) and importin- (green). Arrows indicate regions of extremely similar spatial distributions. Bar, 10 m (field) or 2 m
(zoom).
FIG 4 rAAV2 capsid proteins form an interaction with importin- that can be
dissociated by RanGTP. rAAV2 particles were dissociated by heat and incu-
bated with HEK-293 cell lysate previously transfected with control plasmid or
RanQ69L. Co-IPs were performed using Dynabeads and an anti-importin-
antibody, followed by immunblotting with B1. rAAV2 capsid protein marker,
lanes 1 and 4; control, lanes 2 and 5; RanQ69L, lanes 3 and 6. Identities of
relevant bands are highlighted in bold.
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fectious pathway, we sought to determine which region of the
AAV capsid mediates this interaction. Importin- binds to nucle-
us-bound cargo via classical NLSs (cNLS) but has also been shown
to interact with proteins with nonconventional NLSs. Because the
unique N-terminal regions of VP1 and VP2 contain basic stretches
of amino acids that resemble cNLSs (Fig. 6A), we hypothesized
that one or both of these capsid proteins mediate the interaction
with importin-. To determine which capsid proteins were im-
portant for binding to importin-, we performed co-IPs using
dissociated capsids from particles consisting of all three capsid
proteins, particles with only VP2/VP3, and VP3-only particles,
which were produced as previously described (58). Dissociated
rAAV2 particles with all three capsid proteins or VP2/VP3-only
particles were able to co-IP with importin-; however, VP3-only
particles resulted in limited to nondetectable co-IP (Fig. 6B).
Co-IP utilizing an isotype control antibody also yielded nonde-
tectable product. Interestingly, while co-IP seemed to only require
the presence of VP1 and/or VP2, we were able to detect capsid
protein VP3 in the IP product. We believe this was due to incom-
plete capsid dissociation or oligomerization between NLS-con-
taining capsid proteins and VP3, which may occur after capsid
dissociation.
AAV2 harbors 4 putative NLSs: BR1, located exclusively in
VP1; BR2 and BR3, located in VP1 and VP2; and BR4, located in
all 3 capsid proteins (Fig. 6A). The 4 BR domains have been stud-
ied, and their implications in AAV infectivity have been charac-
terized in detail (23, 25, 26, 47). Mutations to BR1, BR2, and BR3
have been shown to hinder rAAV2 transduction, with mutations
to BR2 and BR3 having the greatest effect on transduction. Since
mutations to BR4 result in defects in capsid assembly (25), we only
investigated mutations to BR1, BR2, and BR3. Therefore, to assess
the contributions of each BR domain in the interaction with im-
portin-, we produced particles with mutations in each of these
BR domains. Consistent with the results presented by Grieger et al.
and Johnson et al. (25, 26), mutations to BR1 alone had a modest
effect on transduction, while mutations to BR2 or BR3 hindered
transduction by over 10-fold in both HeLa cells and HEK-293 cells
(Fig. 6C and data not shown).
We next wanted to determine whether the transduction pro-
files of these mutants are consistent with their capabilities to in-
teract with importin-. Co-IP analysis revealed that while the cap-
sid proteins of rAAV2 interacted with importin-, mutations to
BR2 and BR3 limited this interaction, while mutations to BR1 had
no effect on co-IP (Fig. 6D). The higher-density band seen in the
BR1 co-IP was likely due to higher capsid protein input. Taken
together, our data support that the BR domains, especially BR2
and BR3, are necessary for transduction as they mediate interac-
tions with importin-.
Interaction with importin- is varied among rAAV sero-
types. The majority of information about the infectious pathway
of AAV has been determined for AAV2, with limited understand-











































































FIG 5 Importin- is important for rAAV2 nuclear entry and transduction. (A) HeLa cells were treated with siRNA to importin- or a scrambled siRNA control.
Cell lysate was collected 24 h posttransfection and immunoblotted for importin- levels. (B) HeLa cells were treated with siRNA to KPNB1 (importin-) and
infected with rAAV2-CBA-Luc (1,000 vg/cell) at the indicated times. Luciferase activity was measured 12 h and 24 h postinfection. (C) HeLa cells were treated
with siRNA to KPNB1 and infected with rAAV2-luc at the indicated doses. Luciferase activity was measured 24 h postinfection. (D) HeLa cells were treated with
either scrambled siRNA or siRNA to KPNB1 for 24 h. Cells were pulse-infected with Cy5-labeled rAAV2. At 8 h postinfection, cells were fixed, and confocal
images were acquired to assess nuclear entry of virions. Red, Cy5 fluorescence within cytoplasm; white, nuclear Cy5 fluorescence; DAPI, nucleus; green,
importin-. Bar, 10 m. (E) HeLa cells were treated with siRNA to KPNB1 or a scrambled siRNA and pulse-infected with Cy5-rAAV2 for either 2 or 8 h. Confocal
z-stack images for at least 20 cells per treatment group were acquired. Images were rendered in 3D, and isosurfaces were created for nuclei and Cy5 fluorescence
within each cell. The percent Cy5 fluorescence within nuclei compared to total Cy5 fluorescence within the cell was calculated.
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of VP1up regions of several common AAV serotypes revealed that
most serotypes harbor similar, if not identical, BR domains
(Fig. 7A). The only exception is AAV5, which has a bipartite-like
NLS between BR2 and BR3 rather than two monopartite-like
NLSs. Because these serotypes share similar BR domains, we in-
vestigated whether they interact with importin-. Co-IP analysis
between importin- and dissociated capsid proteins from each
serotype revealed that all viral particles tested interacted with im-
portin-, but to varying extents (Fig. 7B). We measured the co-IP
results by quantifying the ratio of capsid protein product in the
co-IP and the capsid protein applied to the lysate. We found that
rAAV2 had the most robust interaction with importin-, followed
by rAAV1. rAAV5, rAAV6, and rAAV8 were similarly able to in-
teract with importin-, although to a lesser extent than rAAV2
and rAAV1. Finally, we detected interaction, but to a lesser extent,
between rAAV9 and importin-. Interestingly, while rAAV8 and
rAAV9 vectors do not typically transduce HeLa cells, we were still
able to detect interactions between these capsid proteins and im-
portin-. Since our co-IP assay utilizes HeLa cell lysate and dena-
tured capsid proteins, our experimental setup bypasses cellular
barriers such as receptor-mediated endocytosis and endosomal
escape. Thus, it is possible that the use of import proteins such as
importin- is a shared feature of rAAV vectors but occurs down-
stream of initial cellular entry and subcellular trafficking. Our re-
sults suggest that different AAV serotypes utilize alternative im-
port proteins in addition to importin- for nuclear entry.
Analysis of the role of other import proteins in rAAV2 nu-
clear localization. The import protein superfamily consists of
the importin- proteins, importin- adapters, transportins,
and several other importins, such as importin-7 (59, 60). Im-
portin- proteins link nuclear-bound cargo to importin-
through an importin- binding domain. Importin-7 and
transportins can mediate nuclear import independently of im-
portin- (61–63). It has also been shown that importin-7 can
form a cooperative dimer with importin- (62). Studies have
shown that importin- proteins recognize both mono- and
bipartite NLSs and can have redundant functions in host cells
(64–67). Because we established an interaction between rAAV2
and importin-, we investigated if this interaction is mediated
by the importin- adapter proteins. Additionally, we wanted to
identify any potential interactions with the alternative import
proteins importin-7, transportin 1, or transportin 2. Coimmu-
noprecipitation analysis revealed strong interactions between
dissociated rAAV2 capsid proteins and importin-1, impor-
tin-3, and importin-5 (Fig. 8A). Under these conditions, we
did not detect any coimmunoprecipitation between rAAV2
capsid proteins and importin-7, transportin 1, or transportin 2
(data not shown). Interestingly, siRNA knockdown of impor-
tin-1, importin-3, or importin-5 had no effect on rAAV2
transduction 24 h postinfection (Fig. 8B). Similarly, knock-
down of all three importin proteins, to eliminate any compen-
satory function among these proteins, also resulted in no
change in transduction of rAAV2 (data not shown). The im-
portin- superfamily consists of at least 7 known members;
therefore, it is possible that other importin- proteins that
were not identified in this study may also mediate nuclear im-
port of rAAV2. In contrast to our other coimmunoprecipita-
tion data, knockdown of importin-7 reduced transduction by
approximately 60% (Fig. 8B). Taken together, our results sug-
gest that multiple importin- proteins play a role in the import
of AAV2 and may be able to compensate for the depletion of
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FIG 6 BR domains on VP1/VP2 mediate interactions with importin-beta. (A) Schematic of basic regions in rAAV2 VPs and mutations made to ablate NLS
function. The B1 epitope is highlighted. (B) rAAV2 (lane 2), VP2/VP3 (lane 3), and VP3-only (lane 4) particles were dissociated by heat and incubated with HeLa
cell lysate. Co-IPs were performed using Dynabeads and an anti-importin- antibody, followed by immunblotting with B1. Lane 1, capsid protein marker; lane
5, mouse IgG2a isotype control. (C) HeLa cells were infected with rAAV2-CBA-Luc and mutants (1,000 vg/cell). Luciferase activity was measured 24 h
postinfection. Error bars represent standard deviations from three independent samples. (D) Co-IPs were performed with rAAV2 (lane 2), BR1 (lane 3), BR2
(lane 4), and BR3 (lane 5), followed by immunoblotting with B1. Lane 1, capsid protein marker. Relevant band identities are highlighted in bold.
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to be important for transduction, but it may only weakly inter-
act with rAAV2.
DISCUSSION
Mammalian viruses have been shown to utilize components of the
classical nuclear import pathway, including the NPC, nucleo-
porins, and various import proteins. HSV-1 and adenovirus both
directly bind to the cytoplasmic side of the NPC via nucleoporins
(40, 41, 68–71). The adenoviral core protein protein VII has been
shown to bind to several import proteins, including importin-,
importin-, importin-7, and transportin, which are thought to
mediate entry of the nucleoprotein through the NPC (39). Previ-
ous studies have suggested that some viruses, such as HBV and
simian virus 40, may enter the nucleus intact. Two NLSs on the
core protein of HBV become exposed and mediate movement into
the NPC in an importin-- and importin--dependent manner
(42–44, 72). Our data suggesting that rAAV2 utilizes components
of the classical nuclear import machinery to enter the nucleus are
consistent with the mechanism of how other viruses achieve nu-
clear entry. While the current study is limited to characterization
and mechanistic insights utilizing an established cell line, it pro-
vides a foundation for further studies in primary cells and in vivo.
A growing interest in the AAV vector field has focused on under-
standing vector trafficking through host cells, with the notion that
understanding the viral trafficking pathway can lead to the design
of novel vectors that can overcome cellular barriers to transduc-
tion. Our study provides insight into a rate-limiting step of AAV
vector transduction, nuclear entry, and thus the foundation for
novel vector design aimed to expedite this step in subcellular traf-
ficking.
We have shown that blockade of the NPC through microinjec-
tion of WGA followed by infection with rAAV2 inhibits the nu-
clear entry of rAAV2, thus supporting a role for the NPC in rAAV2
nuclear entry. We did not observe complete inhibition of nuclear
entry at this time point, suggesting either reversible inhibition of
nuclear import by WGA, which has previously been reported (73),
or an alternative, NPC-independent pathway that is utilized by
rAAV2. The classical import pathway described herein for rAAV2
differs from the mechanism of nuclear entry proposed by Cohen
et al. for a related parvovirus, MVM (45), and also recent findings
describing nuclear envelope breakdown of permeabilized HeLa
cells by AAV2 that had been acidified and then neutralized (50).
Future work is required to understand how the acidification and
neutralization of rAAV2 mediates nuclear entry under physiolog-
ical subcellular trafficking conditions. It is possible that wt AAV2
and/or rAAV2 can cause nuclear envelope breakdown during in-
fection, but the effects on the nuclear lamina might be more subtle
than what can be detected by fluorescence microscopy. Since the
infectious pathway of rAAV2 differs from that of other autono-
mous parvoviruses, it is not surprising that the mechanisms of
nuclear entry may include both shared and disparate features be-
tween autonomous parvoviruses and nonautonomous parvovi-
ruses. For instance, while proteosome inhibitors have been shown
FIG 7 Interaction with importin- varies among rAAV serotypes. (A) Alignment of the N-terminal regions of VP1 in AAV serotypes. BR domains are outlined
by dashed lines, and a putative bipartite NLS of AAV5 is highlighted with solid lines. (B) rAAV1 (lane 2), -2 (lane 3), -5 (lane 4), -6 (lane 5), -8 (lane 6), and -9
(lane 7) particles were dissociated by heat and incubated with HeLa cell lysate. Co-IP was performed using Dynabeads and an anti-importin- antibody, followed
by immunblotting with B1. Lane 1, capsid protein marker. Relevant band identities are highlighted in bold. (C) Co-IPs were quantified by densitometric
calculation of the co-IP product versus initial input.
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to inhibit the infectivity of MVM and canine parvovirus (CPV)
and have no effect on bovine parvovirus (BPV) (74), it is well
established that proteasome inhibition greatly enhances the nu-
clear entry and transduction of rAAV2 (27, 75). Our results also
differ from a previous report that showed that intact AAV2 could
enter purified nuclei, despite blocking of the pore with WGA or an
antibody to an NPC protein (7), suggesting that the nuclear pore is
dispensable for nuclear entry of AAV2. It is important to note,
however, that the previous study utilized AAV2 virions that had
not gone through physiological endosomal processing, allowing
for the conformational change that exposes the basic regions along
with the PLA2 domain required for transduction. A recent study
by Salganik et al. showed that purified AAV2 virions have external
protease activity at physiological pH that is ablated at low pH (76).
It is possible that virions that traffic to the nucleus using alterna-
tive pathways can exert alternative functions, such as protease-
mediated, NPC-independent nuclear entry under certain condi-
tions. Xiao et al. showed that treatment with thapsigargan, an
inhibitor of cellular calcium flux and modulator of nuclear pore
structure, had no effect on the nuclear entry and subsequent rep-
lication of wt AAV2 in the presence of adenovirus, suggesting that
the nuclear pore was not necessary for AAV2 nuclear entry in a
wild-type context (48). The role of calcium depletion in relation to
nuclear entry through the NPC remains controversial (77), and it
could vary depending on the protein (or virus) being investigated
(78). Furthermore, in addition to inhibiting calcium flux, thapsi-
gargin has many off-target effects, which could have offset any
effects on the nuclear entry of AAV2. Finally, it is possible that the
mechanism of nuclear entry could differ between wild-type AAV2
in the presence of adenovirus and rAAV2 independent of any
helper viruses.
Import proteins, also known as karyopherins, are generally
thought of as chaperones that aid in the translocation of nuclear-
bound cargo. Karyopherins have been implicated in the import of
other viruses, including adenovirus (39), HIV-1 (56, 79–81), in-
fluenza A virus (57, 82–84), HBV (42), and HSV-1 (41). We have
shown that knockdown of importin- inhibits the nuclear trans-
location and transduction of rAAV2, suggesting that importin-
facilitates nuclear import. Furthermore, we have shown that
rAAV2 can codistribute with importin- within cells and form a
Ran-sensitive complex, supporting an interaction that may facil-
itate nuclear entry. Interestingly, while we saw co-IP with impor-
tin-1, -3, and -5, knockdown of these proteins did not affect
transduction. Currently, seven human importin- proteins have
been identified (85), and it is known that these karyopherins can
have both distinct substrate recognition as well as redundant
NLS recognition (86). It is likely that despite knockdown, im-
port of rAAV2 is compensated through the presence of other
importin- proteins and importin-. Furthermore, while we
did not observe co-IP between rAAV2 and importin-7 under
the conditions tested, transduction was inhibited in cells that
had been subjected to importin-7 knockdown. Finally, while a
third class of karyopherins, known as the transportins, have
been shown to be involved with the import of adenovirus, we
saw no coimmunoprecipitation with transportin 1 or transpor-
tin 2 under the conditions tested.
Previous reports have shown that AAV2 contains putative NLS
domains within the unique N-terminal regions of VP1 and VP2
and that mutations to these domains inhibit nuclear entry and
transduction (25, 26). Incorporating one of the BR domains
(BR3) into rAAV2 particles lacking VP1up has been shown to
partially rescue the infectivity of these mutant virions (87). Addi-
tionally, conjugation of BR domains to exogenous green fluores-
cent protein has been shown sufficient to direct this protein to the
nucleus (23, 47). Taken together, these results provide evidence
for the role of the BR domains in rAAV2 nuclear entry. Indeed, we
have shown that while rAAV2 capsid proteins interact with im-
portin- in our co-IP assays, this interaction is ablated when VP1
or VP2 is not available or when BR2 or BR3 has been mutated.
Intriguingly, even though at least one BR domain was still present
in the case of the BR2 and BR3 mutants (i.e., BR3 was available
in the BR2 mutant), we were not able to detect an interaction
with importin- in our co-IP analysis. This observation suggests
that the interaction between importin- and rAAV2 capsid pro-
teins is conformation dependent. Indeed, while the other rAAV
vectors we tested share fairly conserved BR domains, their abilities
to co-IP with importin- varied. Further understanding of the
contributions of serotype-specific domains will be required to un-
derstand the differential interactions between importin- and
other AAV serotypes.
Questions remain about the nuclear translocation efficiency of
rAAV2. Import mediated by importin- has been historically re-
garded as highly efficient and rapid (88). Since our results indi-
cated that the interaction between importin- and rAAV2 was the
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FIG 8 Analysis of additional importin proteins in rAAV2 nuclear entry. (A)
rAAV2 particles were dissociated by heat and incubated with HeLa cell lysate.
Co-IPs were performed using antibodies to importin-1, -3, or -5. Immuno-
blot assays were performed using the B1 antibody. Lanes 1 and 4, capsid pro-
tein marker; lane 2, importin-1 co-IP; lane 3, mouse IgG1 isotype control;
lane 5, importin-3 co-IP; lane 6, importin-5 co-IP; lane 7, rabbit polyclonal
antibody isotype control. (B) Relevant band intensities are highlighted in bold.
HeLa cells were treated with scrambled siRNA (blot, lanes 1, 3, 5, and 7) or to
KPNA2 (importin-1, lane 2), KPNA4 (importin-3, lane 4), KPNA1 (impor-
tin-5, lane 6), or IPO7 (importin-7, lane 8). Luciferase activity was measured
24 h postinfection. Error bars represent standard deviations from a represen-
tative experiment performed in triplicate.
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assume that rAAV2 nuclear entry is the most rapid and efficient as
well. However, Keiser et al. showed that in HeLa cells, rAAV1 and
rAAV5 nuclear entry was initially more efficient than rAAV2 (89).
This same study revealed that rAAV1 and rAAV5 likely utilize
different subcellular trafficking pathways in order to gain access to
the nucleus. Indeed, recent work has demonstrated that while the
microtubule network acts to direct rAAV2 particles to the perinu-
clear region in cells (17), microtubules within the MTOC may also
act as a net, physically trapping virions in this region. This asser-
tion is supported by the fact that application of microtubule-dis-
rupting drugs after rAAV2 has accumulated in the MTOC actually
increases transduction (P. J. Xiao and R. J. Samulski, unpublished
data). Therefore, it is possible that despite efficient interaction
with importin-, rAAV2 nuclear translocation might be physi-
cally impeded by other cellular factors, such as microtubules in the
MTOC. Consistent with this notion, we observed similar cellular
distributions between AAV2 and importin- at the nuclear pe-
riphery up to 9 h postinfection, suggesting that while interactions
may occur between AAV2 and importin-, translocation might be
inhibited by another cellular factor that does not impede translo-
cation of other AAV serotypes. While our data suggest a mecha-
nism for rAAV2 nuclear import through the NPC that is mediated
by importin- and importin- proteins, our findings may only
describe one of several translocation pathways utilized by rAAV
vectors. In fact, recent work by Popa-Wagner et al. identified a
PDZ-binding motif on VP1 that, when mutated, rendered AAV2
defective in nuclear entry. They concluded that this AAV2 PDZ
binding domain might initiate signaling pathways within the
cell to facilitate nuclear entry (49). Moreover, previous work
has shown that AAV2 can interact with the nucleolar proteins
nucleophosmin and nucleolin (27, 90, 91), suggesting that
rAAV2 can translocate into the nucleus through interaction
with these proteins. In addition to the observations of nuclear
envelope breakdown by parvoviruses, including AAV2, Porwal
et al. showed that AAV2 can directly interact with nucleoporins
that comprise the nuclear pore complex (50). Finally, given
that the abundance of karyopherins differs among cell types,
it is possible that rAAV serotypes could utilize different
karyopherins for nuclear entry, which would further contrib-
ute to the differences in cellular tropism historically observed
among the rAAV serotypes.
Based on our results, we have constructed a working model for
the mechanism of nuclear import by rAAV2 (Fig. 9). Upon acid-
ification of the late endosomal compartment and the conforma-
tional change that facilitates the exposure of VP1up, the BR2 and
BR3 domains interact with importin- or an importin-/ com-
plex. rAAV2 could also interact with importin-7 or an importin-
/importin-7 complex. Once rAAV2 escapes the endosomal com-
partment or the MTOC, the virus/importin complex translocates
to the nucleus via the NPC, where subsequent uncoating and gene
expression can occur. Improving the transduction efficiency of
AAV vectors has become paramount to successful gene therapy
applications. While much work has been devoted to discerning the
infectious pathway of AAV vectors, further understanding of spe-
cific trafficking events within host cells is necessary to define cel-
lular barriers to transduction. Ultimately, understanding the de-
tails of viral trafficking and host cell interactions will facilitate the
rational design of AAV vectors that can overcome some of the
trafficking inefficiencies currently observed. Vectors that are more
efficient at navigating the subcellular space in order to deliver their
genetic payload should improve overall gene therapy applications
and clinical outcomes.
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